Navid Kazemi, MD
Cardiovascular Disease · Las Vegas, NVNPI 1346243367
Payments from drug & device makers
Across 329 payments — averaging $473.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$69K
- Amgen$35K
- AstraZeneca$14K
- Boehringer Ingelheim International GmbH$11K
- Medtronic$7K
- Novartis$4K
- plus $14K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 28 | $69,131 |
| Amgen | 25 | $35,423 |
| AstraZeneca | 2 | $14,296 |
| Boehringer Ingelheim International GmbH | 72 | $11,360 |
| Medtronic(3 entities) | 71 | $7,443 |
| Novartis | 2 | $3,989 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $3,558 |
| Abbott | 19 | $2,900 |
| Merck | 12 | $1,560 |
| Penumbra, Inc. | 3 | $1,438 |
| Shockwave Medical, Inc | 7 | $692 |
| Boston Scientific | 5 | $647 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $625 |
| Angiodynamics, Inc. | 4 | $445 |
| Abiomed | 4 | $369 |
| Impulse Dynamics (USA) Inc. | 3 | $364 |
| E.r. Squibb & Sons, L.L.C. | 5 | $252 |
| Cvrx, Inc. | 1 | $195 |
| Cardiva Medical, Inc. | 16 | $179 |
| Edwards Lifesciences | 1 | $166 |
| Pfizer | 2 | $139 |
| Amarin Pharma, Inc. | 22 | $130 |
| Novo Nordisk | 2 | $118 |
| Terumo Medical Corporation | 1 | $113 |
| Chiesi USA, Inc. | 1 | $84 |
| Bard Peripheral Vascular, Inc. | 3 | $68 |
| Alnylam Pharmaceuticals Inc. | 1 | $33 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $5 |
How this compares
$155,760 in reported general payments places this provider in the 95th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Las Vegas
- Ramprasad DandillayaLas Vegas$1.8M
- Chowdhury AhsanLas Vegas$1.4M
- Arjun GururajLas Vegas$399K
- Branavan UmakanthanLas Vegas$109K
- Sanjay MalhotraLas Vegas$101K
- Jawad KianiLas Vegas$73K
- Amish PrasadLas Vegas$58K
- Rafael ValenciaLas Vegas$52K
- Salvador BorromeoLas Vegas$45K
- William ReshLas Vegas$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.